$ACCS ($ACCS) posted quarterly earnings results on Tuesday, November 11th. The company reported earnings of $0.20 per share, beating estimates of $0.12 by $0.08. The company also reported revenue of $5,720,000, missing estimates of $5,790,030 by $-70,030.
You can see Quiver Quantitative's $ACCS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
$ACCS Insider Trading Activity
$ACCS insiders have traded $ACCS stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ACCS stock by insiders over the last 6 months:
- WESLEY T POLLARD purchased 2,000 shares for an estimated $18,420
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ACCS Hedge Fund Activity
We have seen 0 institutional investors add shares of $ACCS stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HERALD INVESTMENT MANAGEMENT LTD added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
- JPMORGAN CHASE & CO added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
- VANGUARD GROUP INC added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
- SBI SECURITIES CO., LTD. added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ACCS Analyst Ratings
Wall Street analysts have issued reports on $ACCS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 08/13/2025
To track analyst ratings and price targets for $ACCS, check out Quiver Quantitative's $ACCS forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
